publication date: Jul. 13, 2018
Issue 28 - Jul. 13, 2018
To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.
  • Immunologists seek ways to make TIL in solid tumors as effective as CAR T in blood cancers

    For more than four decades, Steven Rosenberg’s work on tumor infiltrating lymphocytes has met with equal measures of skepticism and cheer—but now, as more patients across multiple cancer types respond to cell transfer immunotherapy, researchers are eager to join the movement Rosenberg indisputably leads.

  • Conversation with The Cancer Letter

    NCI’s Rosenberg: Tumor infiltrating lymphocytes offer a strategy for treating recalcitrant solid cancers

    After achieving complete regression in several patients with different solid tumor types, Steven Rosenberg is eyeing the biggest prize imaginable—advancing the therapies he has championed for over four decades into the clinic as treatments for commonly occurring cancers.

  • House committee proposes $1.25 billion raise for NIH

    The fiscal year 2019 spending bill marked up by the House Committee on Appropriations gives NIH a $1.25 billion raise.

    “The National Institutes of Health, our nation’s premier biomedical agency, is funded at $1.25 billion above last year’s appropriation,” said Rep. Tom Cole (R-OK), Labor-HHS subcommittee chair.

  • In Brief

    • Gerstle named chief of Pediatric Surgery Service at MSK
    • Pestell joins CytoDyn as chief medical officer
    • Beck named COO at Leukemia & Lymphoma Society
    • UCLA’s Ribas named “Great Immigrant” by Carnegie Corp.
    • Abbott joins the Fox Chase Department of Diagnostic Imaging
  • TCCL Logo

  • Clinical Roundup

    • ACA credited with earlier diagnosis of gynecologic cancers in young women
    • Phase III trial of Ninlaro meets PFS primary endpoint in multiple myeloma
    • New blood test measures four protein biomarkers, can help identify lung cancer
  • Drugs & Targets

    • FDA grants accelerated approval to Yervoy for MSI-H or dMMR metastatic colorectal cancer
    • FDA approves Xtandi sNDA for CRPC
    • FDA grants Priority Review to Merck’s sBLA for Keytruda for advanced hepatocellular carcinoma
    • Genentech submits sNDA for Venclexta for an AML indication

Copyright (c) 2018 The Cancer Letter Inc.